A newly released Drug Discovery Informatics Market analysis report by Future Market Insights reveals that global sales of the Drug Discovery Informatics Market in 2022 were held at USD 2.9 billion. With a CAGR of 14.4% from 2023 to 2033, the market is projected to reach a valuation of USD 12.5 billion by 2033. Discovery Informatics is expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 15% from 2023 to 2033.
| Attribute | Details |
|---|---|
| Global Drug Discovery Informatics Market (2022) | USD 2.9 billion |
| Global Drug Discovery Informatics Market (2033) | USD 12.5 billion |
| Global Drug Discovery Informatics Market CAGR (2023 to 2033) | 14.4% |
| The USA Drug Discovery Informatics Market (2033) | USD 4.1 million |
| Key Companies Profiled | Certara; Boehringer Ingelheim International GmbH; Infosys Ltd.; Charles River Laboratories; Collaborative Drug Discovery, Inc.; Eurofins DiscoverX Products; Jubilant Biosys; Selvita; Novo Informatics Pvt. Ltd.; ChemAxon Ltd.; Albany Molecular Research Inc.; Oracle; Accenture; Agilent Technologies, Inc.; Illumina, Inc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Drug Discovery Informatics Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Drug Discovery Informatics Market increased at around 12.8% CAGR.
Drug Discovery Informatics supports precision medicine, which entails improving the potency of medical care. It improves the effectiveness of Drug Discovery Informatics for particular patient groups based on genetic or molecular profiling.
The growing focus on precision medicine, as well as technological advancements that have resulted in enhanced data storage, management, processing, and analysis, are driving the market. Simultaneously, data collection is critical since new gene sequencing and molecular profiling approaches have dramatically expanded the quantity of data accessible.
Discovery informatics makes the process of discovering and developing novel medications more efficient and streamlined. When compared to the traditional procedure, the time and cost of drug discovery are dramatically reduced.
Committing mistakes in the field of discovery informatics can be very expensive since billions of dollars are invested in the production of each active drug. Such mistakes can be avoided with analytics, which is propelling the industry's growth.
A number of factors such as an increase in research spending on informatics by the pharmaceutical and biotechnology industries drive the global market. Other factors include the emerging demand and abutment for rare disease and orphan drug research combined with increased attention on drug discovery using informatics software.
The rising amount of money spent on informatics research by biotechnology and pharmaceutical businesses is one of the most important factors driving the growth and demand for the Drug Discovery Informatics industry.
Furthermore, the growing need for and support for rare disease and orphan drug research, as well as a growing emphasis on drug discovery using informatics software, will propel the global market forward throughout the forecast period.
Furthermore, another factor fuelling the expansion of the Drug Discovery Informatics business is a diverse set of tools for data gathering, processing, and visualization. Additionally, regional businesses are focusing on the collaboration of research and initiatives. The surge in Healthcare IT industries, the demand for innovative pharmaceuticals in a faster time frame, and infrastructure costs contribute to informatics research's advancement.
Covid-19 has fuelled the rise of the Drug Discovery Informatics industry. Biopharmaceutical firms are investing significant capital toward developing the SARS-COV-2 vaccines. Researchers are evaluating both new and current medications to find treatments to treat the condition, which is propelling the market forward.
A key factor boosting the growth of the market is the emergence of cloud-based technology and new analytics. Cloud computing allows for low-cost storage, processing, and analysis of massive datasets. Faster and better scientific research results from the use of new computers and infrastructural technology.
Cloud computing offers the ability to speed up fundamental research efforts. Another significant factor projected to boost growth in the market is pharmaceutical firms' increasing migration from traditional to data-driven technologies. However, the market for Drug Discovery Informatics can be hampered by costly informatics software price and setup costs, as well as a lack of experienced resources.
Principal Consultant
North America was the largest contributor to the global Drug Discovery Informatics Market in 2022. The regional market will also dominate in the forthcoming years due to the high occurrence rates of various infectious and cancer diseases, as well as the rapid expansion of next-generation sequencing and chemical laboratories.
With the upgrades in the research tools and increasing clinical studies in the Asia Pacific, a similar growth trajectory in the region can be expected. The presence of the pharma nanotechnology sector as well as ongoing software research in the region is also driving growth.
By the end of 2033, the United States is expected to account for the largest market of USD 4.1 billion. It previously grew at a significant CAGR of 12.3% from 2015 to 2022 and is now expected to grow at a CAGR of 14.4% over the forecasted period. A growing emphasis on data-driven solutions by biotech and pharmaceutical companies is one of the factors driving the Drug Discovery Informatics market in the area.
The market in the United Kingdom is expected to reach a valuation of USD 669 million by 2033, growing at a CAGR of 16% from 2023 to 2033. The market is projected to gross an absolute dollar opportunity of USD 514 million during the forecast period.
In Japan, the market is expected to reach a valuation of USD 731 million by 2033. During the forecast period, the market in the country is expected to garner an absolute dollar opportunity of USD 597 million, growing at a CAGR of 18.7%.
The market in South Korea is projected to grow at a CAGR of 12.8% during 2023 to 2033. During this period, the market is projected to witness an absolute dollar opportunity of USD 194 million and reach USD 275 million by 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Discovery Informatics commanded the largest revenue share of the market, and grew at a CAGR of nearly 13.7% from 2018 to 22 and is forecasted to grow at a CAGR of 15.4% throughout the forecasted period.
The substantial share of this market may be due to the rising use of sequencing analysis for novel drug entities and the convenience of managing data from many sources and domains. Precision medicine refers to medical treatment that is tailored to a patient's genetic and molecular profile. Companies have begun to provide discovery informatics solutions in order to use analytics to speed up drug discovery. In addition, governments in several underdeveloped countries are supporting the use of bioinformatics to speed up the development of new medicines.
Sequence Analysis Platforms commanded the largest revenue in this regard and grew at a CAGR of nearly 14.1% from 2018 to 22 and is forecasted to grow at a CAGR of 17% throughout the forecasted period.
Over the projection period, this category will maintain its dominance. Bioinformatics tools are commonly used to create primary and secondary databases of nucleic acid, protein, and other biomolecular sequences. Mining and storage of genome sequencing data are done using informatics tools to discover genes and target proteins, which will aid in the creation of novel medications. Furthermore, fundamental drug discovery research necessitates the use of several databases as well as sequence analysis tools. The advent of new and improved software is also helping to develop the market.
Some of the key companies in the drug discovery informatics market include Certara, Boehringer Ingelheim International GmbH, Infosys Ltd., Charles River Laboratories, Collaborative Drug Discovery, Inc., Eurofins DiscoverX Products, Jubilant Biosys, Selvita, Novo Informatics Pvt. Ltd., ChemAxon Ltd., Albany Molecular Research Inc., Oracle, Accenture, Agilent Technologies, Inc., and Illumina, Inc.
Some of the recent developments of key Drug Discovery Informatics providers are as follows:
In April 2022, Iktos, a provider of Artificial Intelligence for new drug design announced their collaboration with Teijin Pharma Limited to evolve Artificial Intelligence for small molecules drug discovery.
In January 2022, Shanghai Fosun Pharmaceutical collaborated with Insilico Medicine for the discovery and development of drugs utilizing AI technology.
In September 2019, Takeda Pharmaceutical Company Limited and Evotec cooperated to build five drug discovery projects with Evotec clinical candidates for further clinical development by Takeda across different treatment areas.
In August 2019, Certara introduced the 19.6 version of D360, which was the company’s scientific informatics platform for drug discovery and development. This platform enables a scientific researcher to access, exchange, and comprehend data.
In August 2019, Voronoi, a South Korean drug discovery and development biotech firm, has chosen CDD Vault, a hosted platform for storing chemistry and biology data, to handle the firm's joint projects and drug discovery data. Similarly, recent developments related to the companies in Drug Discovery Informatics Market have been tracked by the team at Future Market Insights, which are available in the full report.
The market is expected to reach USD 12.5 billion by 2033.
Certara and Infosys Ltd. are the leading market players.
The market registered a CAGR of 12.8% from 2018 to 2022.
The emergence of cloud-based technology is estimated to boost the market prospects.
The United States is predicted to expand at a CAGR of 14.4% through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technique 5.1. Discovery Informatics 5.1.1. Identification, Validation, & Assay Development Informatics 5.1.2. Lead Generation 5.1.3. Enzymes 5.1.4. Other Cleanings 5.2. Development Informatics 5.2.1. Lead Optimization 5.2.2. FHD Preparation 5.2.3. Phase IA 5.2.4. Phase IB/2 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Mode 6.1. Outsourced 6.2. In-house 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Services 7.1. Sequence Analysis Platforms 7.2. Molecular Modeling 7.3. Docking 7.4. Clinical Trial Data Management 7.5. Other Services 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. PerkinElmer, Inc. 16.2. Thermo Fisher Scientific, Inc. 16.3. Certara, L.P. 16.4. Novo Informatics 16.5. Collaborative Drug Discovery Inc. 16.6. Jubilant Life Sciences Limited 16.7. Selvita 16.8. Charles River Laboratories International, Inc. 16.9. ChemBridge Corporation 16.10. Albany Molecular Research Inc. 16.11. GVK Biosciences 16.12. Agilent Technologies, Inc. 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Drug Discovery Informatics Market
